S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 6, 2009, Pages 963-967

  Hashizume, Toshihiko ^a   Nakada, Yusuke ^a  

^a YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

Author keywords

Oral drugs; Outpatient treatment; Second line chemotherapy

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OUTPATIENT CARE; PROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79959851268     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Shepherd F, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000. (Pubitemid 30324363)
2. Fossella F, DeVore R, Kerr RN, et al: Randomised phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 18: 2354-2362, 2000. (Pubitemid 30415821)
3. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
4. Furuse K, Kawahara M, Hasegawa K, et al: Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small cell lung cancer. Int J Clin Oncol 6: 236-241, 2001. (Pubitemid 33111360)
5. Kawahara M, Furuse K, Segawa Y, et al: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small cell lung cancer. Br J Cancer 85: 939-943, 2001. (Pubitemid 33015993)
6. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004. (Pubitemid 41079796)
7. Ramlau R, Gervais R, Krzakowski M, et al: Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 24: 2800-2807, 2006. (Pubitemid 46630579)
8. Bonomi P, Paz-Ares L, Langer C, et al: Xyotax versus docetaxel for the second-line treatment of non small cell lung cancer: the STELLAR 2 phase III study. Lung Cancer 49: S35, 2005.
9. Krzakowski M, Douillard J, Ramlau R, et al: Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S, 7511, 2007.
10. Takeda K, Negoro S, Tamura T, et al: Docetaxel versus docetaxel plus gemcitabine for second-line treatment of non-small cell lung cancer: results of a JCOG randomized trial (JCOG0104). J Clin Oncol, ASCO Annual Meeting Proceedings. Vol 22, No. 14S, 7034, 2004.
11. Wachters FM, Groen HJ, Biesma B, et al: A randomized phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage III b-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92: 15-20, 2005. (Pubitemid 40188429)
12. Pectasides D, Pectasides M, Farmakis D, et al: Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16: 294-299, 2005. (Pubitemid 40309313)